Page last updated: 2024-10-30

memantine and Dementia Praecox

memantine has been researched along with Dementia Praecox in 45 studies

Research Excerpts

ExcerptRelevanceReference
"To integrate all evidence derived from randomized controlled trials (RCTs) of both pharmacological and nonpharmacological augmentation interventions for clozapine-resistant schizophrenia (CRS)."9.41Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment. ( Carvalho, AF; Chen, MH; Chu, CS; Correll, CU; Hsu, CW; Il Shin, J; Liang, CS; Stubbs, B; Thompson, T; Tseng, PT; Tu, YK; Yang, FC; Yang, SN; Yeh, TC; Yu, CL, 2023)
"Our study gives further evidence that memantine add-on treatment to risperidone may have neuroprotective effects and improve cognitive function in patients with schizophrenia."9.34Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020)
"The uncompetitive low-affinity NMDA receptor antagonist, memantine, acutely increases electrophysiological measures of auditory information processing in both healthy subjects (HS) and patients with schizophrenia."9.34Memantine effects on auditory discrimination and training in schizophrenia patients. ( Bhakta, SG; Clifford, RE; Joshi, YB; Kotz, J; Light, GA; Molina, JL; Roberts, BZ; Swerdlow, NR; Talledo, J; Thomas, ML, 2020)
"This study shows that, add-on memantine would be helpful, in the adjunctive treatment of depressive, positive, negative and general symptoms in patients with schizophrenia."9.24The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial. ( Maracy, MR; Mohammadian-Sichani, M; Omranifard, V; Rajabi, F, 2017)
"In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia."9.24Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. ( de Haan, L; Deijen, JB; Schulte, PF; Veerman, SR, 2017)
"In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects."9.22Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016)
"We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia."9.17Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Hajiaghaee, R; Hammidi, S; Modabbernia, A; Mohammad-Karimi, M; Motasami, H; Rezaei, F; Salehi, B; Seddighi, S; Tabrizi, M, 2013)
"Memantine add-on to clozapine therapy was associated with improvement in negative and positive symptoms in refractory schizophrenia patients."9.14Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. ( Belmonte-de-Abreu, PS; Berk, M; de Lucena, D; Dodd, S; Fernandes, BS; Gama, CS; Giglio, LF; Gomes, FA; Kunz, M; Lobato, MI; Medeiros, DW; Pedrini, M, 2009)
"Memantine addition to antipsychotic treatment, in schizophrenia patients might improve their clinical status, primarily the negative signs, but not their cognitive deficits."9.13Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. ( Fischel, T; Hellinger, N; Krivoy, A; Laor, L; Weizman, A; Zemishlany, Z, 2008)
"Memantine augmentation treatment seems to be beneficial for particularly treating negative symptoms in schizophrenia patients."9.01Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. ( Anıl Yağcıoğlu, AE; Karahan, S; Vayısoğlu, S, 2019)
"This meta-analysis showed that adjunctive memantine appears to be an efficacious and safe treatment for improving negative symptoms and neurocognitive performance in schizophrenia."8.98Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. ( Cai, DB; Li, XH; Ng, CH; Ning, YP; Ungvari, GS; Wang, SB; Wang, YY; Xiang, YT; Yang, XH; Zheng, W, 2018)
"We analyzed double-blind, randomized, placebo-controlled trials of memantine add-on treatment in schizophrenia patients receiving antipsychotics."7.85Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. ( Iwata, N; Kishi, T; Matsuda, Y, 2017)
"We report here the results of a chart review-based retrospective case series study that examined the effectiveness of off-label use of memantine in patients with schizophrenia when used as adjunctive therapy to standard neuroleptic therapy."7.80Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. ( John, JP; Lukose, A; Manjunath, S, 2014)
" Recently, glutamate-based strategies, such as memantine add-on to antipsychotics, have been proposed for refractory symptoms of schizophrenia, e."7.80Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Sarappa, C; Tomasetti, C, 2014)
"Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist."6.72Memantine in neurological disorders - schizophrenia and depression. ( Chuchmacz, J; Czarnecka, K; Szymański, P; Wójtowicz, P, 2021)
"To integrate all evidence derived from randomized controlled trials (RCTs) of both pharmacological and nonpharmacological augmentation interventions for clozapine-resistant schizophrenia (CRS)."5.41Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment. ( Carvalho, AF; Chen, MH; Chu, CS; Correll, CU; Hsu, CW; Il Shin, J; Liang, CS; Stubbs, B; Thompson, T; Tseng, PT; Tu, YK; Yang, FC; Yang, SN; Yeh, TC; Yu, CL, 2023)
"Our study gives further evidence that memantine add-on treatment to risperidone may have neuroprotective effects and improve cognitive function in patients with schizophrenia."5.34Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020)
"The uncompetitive low-affinity NMDA receptor antagonist, memantine, acutely increases electrophysiological measures of auditory information processing in both healthy subjects (HS) and patients with schizophrenia."5.34Memantine effects on auditory discrimination and training in schizophrenia patients. ( Bhakta, SG; Clifford, RE; Joshi, YB; Kotz, J; Light, GA; Molina, JL; Roberts, BZ; Swerdlow, NR; Talledo, J; Thomas, ML, 2020)
"This study shows that, add-on memantine would be helpful, in the adjunctive treatment of depressive, positive, negative and general symptoms in patients with schizophrenia."5.24The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial. ( Maracy, MR; Mohammadian-Sichani, M; Omranifard, V; Rajabi, F, 2017)
"In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia."5.24Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. ( de Haan, L; Deijen, JB; Schulte, PF; Veerman, SR, 2017)
"In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects."5.22Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016)
"We aimed to evaluate the efficacy of memantine add-on in the treatment of primary negative symptoms of patients with stable schizophrenia."5.17Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Hajiaghaee, R; Hammidi, S; Modabbernia, A; Mohammad-Karimi, M; Motasami, H; Rezaei, F; Salehi, B; Seddighi, S; Tabrizi, M, 2013)
"Memantine add-on to clozapine therapy was associated with improvement in negative and positive symptoms in refractory schizophrenia patients."5.14Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. ( Belmonte-de-Abreu, PS; Berk, M; de Lucena, D; Dodd, S; Fernandes, BS; Gama, CS; Giglio, LF; Gomes, FA; Kunz, M; Lobato, MI; Medeiros, DW; Pedrini, M, 2009)
"Memantine addition to antipsychotic treatment, in schizophrenia patients might improve their clinical status, primarily the negative signs, but not their cognitive deficits."5.13Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. ( Fischel, T; Hellinger, N; Krivoy, A; Laor, L; Weizman, A; Zemishlany, Z, 2008)
"Memantine augmentation treatment seems to be beneficial for particularly treating negative symptoms in schizophrenia patients."5.01Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. ( Anıl Yağcıoğlu, AE; Karahan, S; Vayısoğlu, S, 2019)
"Fifteen RCTs (n = 988) examining memantine (5-20 mg/day) as an adjunct treatment for schizophrenia (9 trials with 512 patients), bipolar disorder (3 trials with 319 patients), and MDD (3 trials with 157 patients) were analyzed."5.01Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials. ( Cai, DB; He, SH; Ng, CH; Ning, YP; Peng, XJ; Ungvari, GS; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W; Zhou, YL; Zhu, XM, 2019)
"This meta-analysis showed that adjunctive memantine appears to be an efficacious and safe treatment for improving negative symptoms and neurocognitive performance in schizophrenia."4.98Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. ( Cai, DB; Li, XH; Ng, CH; Ning, YP; Ungvari, GS; Wang, SB; Wang, YY; Xiang, YT; Yang, XH; Zheng, W, 2018)
"We analyzed double-blind, randomized, placebo-controlled trials of memantine add-on treatment in schizophrenia patients receiving antipsychotics."3.85Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. ( Iwata, N; Kishi, T; Matsuda, Y, 2017)
" Recently, glutamate-based strategies, such as memantine add-on to antipsychotics, have been proposed for refractory symptoms of schizophrenia, e."3.80Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. ( Buonaguro, EF; de Bartolomeis, A; Eramo, A; Iasevoli, F; Latte, G; Marmo, F; Rossi, R; Sarappa, C; Tomasetti, C, 2014)
"We report here the results of a chart review-based retrospective case series study that examined the effectiveness of off-label use of memantine in patients with schizophrenia when used as adjunctive therapy to standard neuroleptic therapy."3.80Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. ( John, JP; Lukose, A; Manjunath, S, 2014)
"Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist."2.72Memantine in neurological disorders - schizophrenia and depression. ( Chuchmacz, J; Czarnecka, K; Szymański, P; Wójtowicz, P, 2021)
"Schizophrenia is a devastating psychiatric illness."2.41Imaging the glutamatergic system in vivo--relevance to schizophrenia. ( Bressan, RA; Pilowsky, LS, 2000)
"Schizophrenia is a severe, disabling chronic disorder affecting approximately 1% of the population."1.37Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. ( Dedeurwaerdere, S; Langlois, X; Pemberton, D; Straetemans, R; Wintmolders, C, 2011)

Research

Studies (45)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (22.22)29.6817
2010's27 (60.00)24.3611
2020's8 (17.78)2.80

Authors

AuthorsStudies
Yeh, TC2
Correll, CU2
Yang, FC2
Chen, MH2
Tseng, PT2
Hsu, CW2
Carvalho, AF2
Stubbs, B2
Thompson, T2
Chu, CS2
Yu, CL2
Il Shin, J2
Yang, SN2
Tu, YK2
Liang, CS2
Schaefer, M2
Sarkar, S1
Theophil, I1
Leopold, K2
Heinz, A2
Gallinat, J1
Martin, ED1
Deardorff, OG1
Menditto, AA1
Sethi, S1
Hopkins, TM1
Li, H1
Xing, M1
Zhang, C1
Molina, JL2
Voytek, B1
Thomas, ML2
Joshi, YB3
Bhakta, SG3
Talledo, JA3
Swerdlow, NR6
Light, GA5
Vayısoğlu, S1
Karahan, S1
Anıl Yağcıoğlu, AE1
Kikuchi, T1
Talledo, J1
Kotz, J1
Roberts, BZ1
Clifford, RE1
Czarnecka, K1
Chuchmacz, J1
Wójtowicz, P1
Szymański, P1
Zhang, W1
Bhakta, S2
Kishi, T3
Matsuda, Y3
Iwata, N3
Zheng, W2
Li, XH1
Yang, XH2
Cai, DB2
Ungvari, GS2
Ng, CH2
Wang, SB1
Wang, YY1
Ning, YP2
Xiang, YT2
Omranifard, V1
Rajabi, F1
Mohammadian-Sichani, M1
Maracy, MR1
Koola, MM2
Sklar, J1
Davis, W1
Nikiforuk, A1
Meissen, JK1
Sawant-Basak, A1
Aaronson, ST2
Kozak, R1
Ikuta, T1
Veerman, S1
Schulte, P1
de Haan, L4
Kantrowitz, JT1
Dunn, W1
Vinogradov, S1
Sekar, S1
Grandjean, J1
Garnell, JF1
Willems, R1
Duytschaever, H1
Seramani, S1
Su, H1
Ver Donck, L1
Bhakoo, KK1
Uribe, E1
Fernández, L2
Pacheco, D1
Nayadoleni, N1
Eblen-Zajjur, A1
Zhu, XM1
Zhang, QE1
Zhou, YL1
He, SH1
Peng, XJ1
Rezaei, F1
Mohammad-Karimi, M1
Seddighi, S1
Modabbernia, A1
Ashrafi, M1
Salehi, B1
Hammidi, S1
Motasami, H1
Hajiaghaee, R1
Tabrizi, M1
Akhondzadeh, S1
Ene-Stroescu, V1
Nguyen, T1
Waiblinger, BE1
Buchanan, RW1
Pillai, A1
Aitchison, KJ1
Weinberger, DR1
Dickerson, FB1
Veerman, SR3
Schulte, PF3
Iasevoli, F1
Buonaguro, EF1
Sarappa, C1
Marmo, F1
Latte, G1
Rossi, R1
Eramo, A1
Tomasetti, C1
de Bartolomeis, A1
John, JP1
Lukose, A1
Manjunath, S1
Chou, HH1
Balvaneda, B1
Smith, JD1
Deijen, JB1
Mazinani, R1
Nejati, S1
Khodaei, M1
Fakhri, A1
Pakseresht, S1
Haghdoost, MR1
Hekmatkhah, N1
Torkashvand, M1
Ghorbanzadeh, B1
Lieberman, JA1
Papadakis, K1
Csernansky, J1
Litman, R1
Volavka, J1
Jia, XD1
Gage, A1
de Lucena, D2
Fernandes, BS2
Berk, M1
Dodd, S1
Medeiros, DW1
Pedrini, M1
Kunz, M2
Gomes, FA1
Giglio, LF1
Lobato, MI1
Belmonte-de-Abreu, PS2
Gama, CS3
Fries, GR1
Stertz, L1
Aguiar, B1
Pfaffenseller, B1
Dedeurwaerdere, S1
Wintmolders, C1
Straetemans, R1
Pemberton, D1
Langlois, X1
Kato, T1
Rands, GS1
Antunes, P1
Moser, C1
Hinzpeter, A1
Krebs, M1
Krivoy, A1
Weizman, A1
Laor, L1
Hellinger, N1
Zemishlany, Z1
Fischel, T1
Cerullo, MA1
Adler, CM1
Strakowski, SM1
Eliassen, JC1
Nasrallah, HA1
Nasrallah, AT1
Zdanys, K1
Tampi, RR1
Bressan, RA1
Pilowsky, LS1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study[NCT00148590]Phase 324 participants (Actual)Interventional2005-11-30Terminated
Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Chronic Schizophrenia: Results of a Proof of Concept Study[NCT00148616]Phase 313 participants (Actual)Interventional2004-04-30Terminated
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia[NCT03860597]Phase 442 participants (Actual)Interventional2018-04-01Completed
Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia: A Randomized, Group Sequential Adaptive Design, Controlled Clinical Trial[NCT05944510]Phase 472 participants (Anticipated)Interventional2023-08-31Recruiting
Analysis of Parameters Indicating the Intensity of Suicidal Behavior in Patients Suffering From Depression and Schizophrenia[NCT05803447]120 participants (Actual)Observational2016-09-01Completed
A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?[NCT02234752]Phase 23 participants (Actual)Interventional2014-09-30Terminated (stopped due to Funding no longer available and PI no longer working at the institution)
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684]Phase 282 participants (Actual)Interventional2014-07-01Completed
Phase 4 Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms in Patients Using Clozapine. A Randomized, Double-Blind, Placebo Controled Study[NCT00757978]Phase 422 participants (Actual)Interventional2006-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

"Gamma Auditory Steady-state Response (ASSR). The Primary Unit of Measure of Auditory Steady State Response (ASSR) is Gamma Evoked Power (γEP), Expressed as Microvolts-squared."

1 ms, 85 dB clicks were presented in 500 ms trains at a frequency of 40 Hz; 250 click trains were played (inter-train interval=0.5 s). EEG was continuously recorded with 64-channel BioSemi ActiveTwo system (sampling rate=2048 Hz). Data processed offline via Matlab, EEGlab, & BrainVision Analyzer. Continuous data were segmented relative to stimulus onset (-100 ms to 500 ms) & each epoch was baseline-corrected relative to 100 ms pre-stimulus interval. γEP was assessed based on first 100 artifact-free epochs at Fz. Averaged epochs across click trains were transformed into power spectrum via fast Fourier transform using a bin width of 2 Hz. 40 Hz power spectrum was averaged across 4 Hz band from 38-42 Hz. Data were analyzed by RM-ANOVA, with diagnosis as a between- & drug condition (placebo vs MEM) as a within-subject factor. Analyses revealed robust & time bin-independent effects of diagnosis & drug across 200-500 ms window & thus this interval was the focus of all subsequent analyses. (NCT03860597)
Timeframe: 7 and 14 days post baseline

,,,
InterventionMicrovolts-squared (Mean)
PlaceboMemantine
Healthy Subjects: 20 mg Memantine 1st, Then Placebo0.140.23
Healthy Subjects: Placebo 1st, Then 20 mg Memantine0.140.23
Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo0.070.06
Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine0.080.09

Mismatch Negativity (MMN); Unit of Measure of MMN is Microvolts.

85 dB SPL stimuli were presented via Etymotic ER3-A insert earphones. A 4-tone auditory oddball paradigm with 82% standards & 18% deviant stimuli, differed from standard in pitch, duration, or both. A pseudorandomized sequence produced a minimum of 3 standard tones between each deviant stimulus. All tones had 5-ms rise/fall times presented with a fixed 500-ms stimulus onset asynchrony. Subjects viewed a silent movie & instructed to ignore auditory stimuli. EEG were continuously recorded at a sampling rate of 2048-Hz from 64 channels, using BioSemi ActiveTwo system & downsampled to 512-Hz. Deviant-minus-standard difference waves were generated for each deviant type & low-pass filtered (20-Hz zerophase shift, 24 dB/octave rolloff). MMN was computed as mean amplitude across 135-205 ms range for each deviant type in difference waveforms at electrode Fz. Data were analyzed by RM-ANOVA, with diagnosis as a between-subject factor, & drug condition (placebo vs MEM) as a within-subject factor. (NCT03860597)
Timeframe: 7 and 14 days post baseline

,,,
Interventionmicrovolts (Mean)
PlaceboMemantine
Healthy Subjects: 20 mg Memantine 1st, Then Placebo-3.52-3.28
Healthy Subjects: Placebo 1st, Then 20 mg Memantine-3.52-3.28
Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo-1.60-1.70
Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine-3.15-2.44

Prepulse Inhibition (PPI)

"PPI of the startle reflex is the automatic reduction in startle magnitude (assessed by EMG of orbicularis oculi) when a startling stimulus (40 ms 118 dB(A) noise burst; PULSE) is preceded (10-120 msec) by a weak stimulus (here a 20 msec burst 16 dB over background PREPULSE). A %PPI metric is calculated based on the relative startle magnitude on (PREPULSE + PULSE) trials vs. PULSE alone trials. Possible maximal inhibition is 100%; there is no maximal negative value of inhibition. There is no clear advantage or disadvantage for lower or higher %PPI values, though on average, schizophrenia patients demonstrate lower % values compared to matched healthy subjects. Day 1 was baseline testing: testing occurred, data was collected, but no intervention was given. There were two possible interventions: active (MEM 20 mg po) and placebo. One intervention was given on day 7 post baseline, the other intervention was given on day 14 post baseline, with order of intervention balanced." (NCT03860597)
Timeframe: 7 and 14 days post baseline

,,,
Intervention% inhibition of startle (Mean)
PlaceboMemantine
Healthy Subjects: 20 mg Memantine 1st, Then Placebo11.7825.55
Healthy Subjects: Placebo 1st, Then 20 mg Memantine14.1121.36
Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo26.8520.55
Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine32.4510.11

Change in Level of Cognition

The primary outcome measure will be the change in level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). In schizophrenia, usual composite scores are 20-39. In healthy controls, usual composite scores are normalized to 40-60. Higher values of composite scores mean better cognition. Test scores are normalized to healthy controls, therefore no min-max range is available. Final scores calculated by MATRICS Consensus Cognitive Battery software. Exact minimum/maximum are not known to provider. Overall composite scores are reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks

Interventionunits on a scale (Number)
Baseline Participant 1Week 6 Participant 1Baseline Participant 2Week 6 Participant 2Baseline Participant 3
Galantamine ER, Memantine XR484832259

Free Tryptophan (TRP)

The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. (NCT02234752)
Timeframe: Baseline and 6-Weeks

InterventionµM (Mean)
Baseline tryptophan Participant 1Week-6 tryptophan Participant 1Baseline tryptophan Participant 2Week-6 tryptophan Participant 2Baseline tryptophan Participant 3
KP Metabolites Values51.9455.7232.1724.9635.07

KYN/TRP

The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks

InterventionAUC Ratio (Number)
Baseline KYN/TRP Participant 1Week-6 KYN/TRP Participant 1Baseline KYN/TRP Participant 2Week-6 KYN/TRP Participant 2Baseline KYN/TRP Participant 3
KP Metabolites Values1.211.311.060.80.79

KYNA/KYN

The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks

InterventionAUC Ratio (Number)
Baseline KYNA/KYN Participant 1Week-6 KYNA/KYN Participant 1Baseline KYNA/KYN Participant 2Week-6 KYNA/KYN Participant 2Baseline KYNA/KYN Participant 3
KP Metabolites Values0.0750.0500.1210.1140.152

Kynurenic Acid (KYNA)

The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. MS* AUC is mass spectrometry times area under the curve. (NCT02234752)
Timeframe: Baseline and 6-Weeks

InterventionMS* AUC (Mean)
Baseline KYNA Participant 1Week-6 KYNA Participant 1Baseline KYNA Participant 2Week-6 KYNA Participant 2Baseline KYNA Participant 3
KP Metabolites Values10391183737951397328093163

Kynurenine (KYN)

The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. (NCT02234752)
Timeframe: Baseline and 6-Weeks

InterventionµM (Mean)
Baseline KYN Participant 1Week-6 KYN Participant 1Baseline KYN Participant 2Week-6 KYN Participant 2Baseline KYN Participant 3
KP Metabolites Values1.621.850.860.710.76

PIC/KYN

The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks

InterventionAUC Ratio (Number)
Baseline PIC/KYN Participant 1Week-6 PIC/KYN Participant 1Baseline PIC/KYN Participant 2Week-6 PIC/KYN Participant 2Baseline PIC/KYN Participant 3
KP Metabolites Values0.03170.01750.10390.09890.0655

Picolinic Acid (PIC)

The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. MS* AUC is mass spectrometry times area under the curve. (NCT02234752)
Timeframe: Baseline and 6-Weeks

InterventionMS* AUC (Mean)
Baseline PIC Participant 1Week-6 PIC Participant 1Baseline PIC Participant 2Week-6 PIC Participant 2Baseline PIC Participant 3
KP Metabolites Values4402129542818836374540189

MATRICS Consensus Cognitive Battery Performance (MCCB)

The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionstandardized T-score (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo57.87056.000
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine54.47655.476
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo39.89538.105
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine31.89533.842

Prepulse Inhibition (PPI)

"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Intervention% inhibition of startle (Mean)
PlaceboAmphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo50.62653.029
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine50.62645.822
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo41.16239.545
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine22.62932.656

Targeted Cognitive Training (TCT): PositScience, Inc.

"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionmsec (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo-2.11329.190
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine5.91135.905
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo-50.158101.000
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine-15.11852.647

Reviews

13 reviews available for memantine and Dementia Praecox

ArticleYear
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
    Asian journal of psychiatry, 2023, Volume: 79

    Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch

2023
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
    Asian journal of psychiatry, 2023, Volume: 79

    Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch

2023
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
    Asian journal of psychiatry, 2023, Volume: 79

    Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch

2023
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
    Asian journal of psychiatry, 2023, Volume: 79

    Topics: Antipsychotic Agents; Clozapine; Entropy; Humans; Memantine; Mirtazapine; Network Meta-Analysis; Sch

2023
Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis.
    Turk psikiyatri dergisi = Turkish journal of psychiatry, 2019,Winter, Volume: 30, Issue:4

    Topics: Antiparkinson Agents; Antipsychotic Agents; Drug Therapy, Combination; Humans; Memantine; Psychiatri

2019
Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
    Biomolecules, 2020, 07-31, Volume: 10, Issue:8

    Topics: Animals; Antipsychotic Agents; Drug Combinations; Excitatory Amino Acid Antagonists; Humans; Memanti

2020
Memantine in neurological disorders - schizophrenia and depression.
    Journal of molecular medicine (Berlin, Germany), 2021, Volume: 99, Issue:3

    Topics: Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Clinical Trials as Topic; Depression

2021
Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Psychological medicine, 2018, Volume: 48, Issue:1

    Topics: Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Memantine; Psychiatric

2018
Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2018, Volume: 3, Issue:7

    Topics: Auditory Perception; Cognitive Dysfunction; Excitatory Amino Acid Agonists; Excitatory Amino Acid An

2018
Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials.
    Schizophrenia research, 2019, Volume: 209

    Topics: Bipolar Disorder; Cognition; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combinat

2019
Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials.
    Journal of psychiatric research, 2013, Volume: 47, Issue:12

    Topics: Antipsychotic Agents; Humans; Memantine; Randomized Controlled Trials as Topic; Receptors, N-Methyl-

2013
Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.
    Schizophrenia research, 2014, Volume: 157, Issue:1-3

    Topics: Animals; Cognition Disorders; Drug Therapy, Combination; Galantamine; Humans; Memantine; Nootropic A

2014
The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged.
    Pharmacopsychiatry, 2014, Volume: 47, Issue:4-5

    Topics: Clozapine; Drug Delivery Systems; Drug Therapy, Combination; Excitatory Amino Acid Agonists; Excitat

2014
[Role of magnesium ions on the regulation of NMDA receptor--a pharmacopathology of memantine].
    Clinical calcium, 2004, Volume: 14, Issue:8

    Topics: Alzheimer Disease; Binding Sites; Brain Ischemia; Dizocilpine Maleate; Humans; Magnesium; Memantine;

2004
A systematic review of off-label uses of memantine for psychiatric disorders.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Aug-01, Volume: 32, Issue:6

    Topics: Anxiety; Bipolar Disorder; Bulimia Nervosa; Child; Child Development Disorders, Pervasive; Depressio

2008
Imaging the glutamatergic system in vivo--relevance to schizophrenia.
    European journal of nuclear medicine, 2000, Volume: 27, Issue:11

    Topics: Brain Chemistry; Humans; Ketamine; Memantine; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Gl

2000

Trials

16 trials available for memantine and Dementia Praecox

ArticleYear
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
    Pharmacopsychiatry, 2020, Volume: 53, Issue:1

    Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th

2020
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
    Pharmacopsychiatry, 2020, Volume: 53, Issue:1

    Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th

2020
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
    Pharmacopsychiatry, 2020, Volume: 53, Issue:1

    Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th

2020
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
    Pharmacopsychiatry, 2020, Volume: 53, Issue:1

    Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th

2020
Memantine Effects on Electroencephalographic Measures of Putative Excitatory/Inhibitory Balance in Schizophrenia.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:6

    Topics: Double-Blind Method; Electroencephalography; Excitatory Amino Acid Antagonists; Humans; Memantine; S

2020
Memantine effects on auditory discrimination and training in schizophrenia patients.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020, Volume: 45, Issue:13

    Topics: Auditory Perception; Discrimination, Psychological; Double-Blind Method; Humans; Memantine; Receptor

2020
Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017, Volume: 42, Issue:13

    Topics: Adult; Antipsychotic Agents; Auditory Perception; Chronic Disease; Cortical Synchronization; Cross-O

2017
The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial.
    Actas espanolas de psiquiatria, 2017, Volume: 45, Issue:3

    Topics: Adult; Antipsychotic Agents; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Hum

2017
Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.
    Schizophrenia research, 2018, Volume: 193

    Topics: Adolescent; Adult; Cognitive Dysfunction; Drug Therapy, Combination; Female; Galantamine; Humans; Ky

2018
Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:3

    Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Excitatory Amino Acid A

2013
Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
    Psychological medicine, 2016, Volume: 46, Issue:9

    Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Meth

2016
Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.
    Psychological medicine, 2017, Volume: 47, Issue:2

    Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Drug Resistance; Drug Synergism; Drug

2017
Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial.
    Psychiatry research, 2017, Volume: 247

    Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Drug Therapy, Combination; Female; Huma

2017
Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
    Acta medica Iranica, 2016, Volume: 54, Issue:11

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-B

2016
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:5

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Excit

2009
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:10

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Double-Bli

2009
Lack of association between serum brain-derived neurotrophic factor levels and improvement of schizophrenia symptoms in a double-blind, randomized, placebo-controlled trial of memantine as adjunctive therapy to clozapine.
    The Journal of clinical psychiatry, 2010, Volume: 71, Issue:1

    Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Clozapine; Dopamine Agents; Double-Blind Me

2010
Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2008, Volume: 18, Issue:2

    Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Cognition Disorders; Female; Humans; Inpatients;

2008
Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study.
    Schizophrenia research, 2007, Volume: 97, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Dominance, Cerebral; Dopamine Agents; Double-Blind Method; Drug Therapy

2007

Other Studies

16 other studies available for memantine and Dementia Praecox

ArticleYear
Adjunct memantine for clozapine rechallenge following cardiomyopathy.
    Schizophrenia research, 2020, Volume: 218

    Topics: Antipsychotic Agents; Cardiomyopathies; Clozapine; Humans; Memantine; Schizophrenia

2020
Antipsychotics-associated obsessive-compulsive symptoms: individualized treatments and clinical benefits of memantine: a case report.
    Annals of palliative medicine, 2020, Volume: 9, Issue:2

    Topics: Adult; Antipsychotic Agents; Humans; Male; Memantine; Obsessive-Compulsive Disorder; Schizophrenia;

2020
Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.
    Psychopharmacology, 2017, Volume: 234, Issue:14

    Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Humans; Memantine; Risperidone; Schizop

2017
Response to the letter from Dr. Veerman and colleagues.
    Psychopharmacology, 2017, Volume: 234, Issue:23-24

    Topics: Antipsychotic Agents; Cognition; Humans; Memantine; Schizophrenia

2017
Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia.
    Psychopharmacology, 2017, Volume: 234, Issue:23-24

    Topics: Antipsychotic Agents; Clozapine; Cognition; Humans; Memantine; Schizophrenia

2017
Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge.
    Schizophrenia research, 2018, Volume: 199

    Topics: Animals; Antipsychotic Agents; Auditory Perception; Humans; Learning; Memantine; Neuronal Plasticity

2018
Neuro-metabolite profiles of rodent models of psychiatric dysfunctions characterised by MR spectroscopy.
    Neuropharmacology, 2019, 03-01, Volume: 146

    Topics: Anhedonia; Animals; Choline; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists;

2019
Administration of memantine reverses behavioral, histological, and electrophysiological abnormalities in rats subjected to early maternal deprivation.
    Journal of neural transmission (Vienna, Austria : 1996), 2019, Volume: 126, Issue:6

    Topics: Animals; Animals, Newborn; Auditory Cortex; Behavior, Animal; Cognitive Dysfunction; Corpus Striatum

2019
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy.
    The Journal of neuropsychiatry and clinical neurosciences, 2014,Winter, Volume: 26, Issue:1

    Topics: Adolescent; Amantadine; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Atrophy; Catato

2014
Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia.
    Progress in neuro-psychopharmacology & biological psychiatry, 2014, Oct-03, Volume: 54

    Topics: Animals; Benzazepines; Brain; Carrier Proteins; Disks Large Homolog 4 Protein; Dopamine; Dopamine Ag

2014
Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study.
    Pharmacopsychiatry, 2014, Volume: 47, Issue:6

    Topics: Adult; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Male; Memantine; Middle Aged; Psy

2014
Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2016, Volume: 41, Issue:2

    Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Habituatio

2016
Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist.
    Psychopharmacology, 2011, Volume: 214, Issue:2

    Topics: Analysis of Variance; Animals; Antipsychotic Agents; Autoradiography; Biological Transport; Brain; B

2011
Memantine as a neuroprotective treatment in schizophrenia.
    The British journal of psychiatry : the journal of mental science, 2005, Volume: 186

    Topics: Calcium; Glutamic Acid; Humans; Memantine; Neurons; Receptors, N-Methyl-D-Aspartate; Schizophrenia

2005
[Memantine as an adjunctive therapy for schizophrenia negative symptoms].
    Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2005, Volume: 27, Issue:3

    Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; Memantine; Middle Aged; Rece

2005
Memantine-associated reversal of clozapine-induced weight gain.
    Pharmacopsychiatry, 2007, Volume: 40, Issue:4

    Topics: Adult; Antipsychotic Agents; Clozapine; Dopamine Agents; Humans; Male; Memantine; N-Methylaspartate;

2007
chemdatabank.com